Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: An open-label trial

Japanese Journal of Clinical Oncology

Volumn 38, Issue 4, 2008, Pages 296-304

  Narabayashi, Masaru ^a   Saijo, Yasuo ^b   Takenoshita, Seiichi ^c   Chida, Masayuki ^d   Shimoyama, Naohito ^e   Miura, Takeshi ^f   Tani, Kazuhiko ^g   Nishimura, Kousuke ^h   Onozawa, Yusuke ⁱ   Hosokawa, Toyoshi ^j   Kamoto, Toshiyuki ^k,l   Tsushima, Tomoyasu ^l  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d Ota Nishinouchi Hospital   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^h Gifu Central Hospital   (Japan)

ⁱ SHIZUOKA CANCER CENTER   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^k KYOTO UNIVERSITY   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

more..

Author keywords

Cancer pain; Morphine; Opioid rotation; Oxycodone; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; CREATININE; FENTANYL; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; OXYMORPHONE;

ADULT; AGED; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; KIDNEY FUNCTION; LUNG CANCER; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PANCREAS CANCER; PRURITUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; AGED; ANALGESICS, OPIOID; CONSTIPATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MORPHINANS; MORPHINE; MORPHINE DERIVATIVES; NAUSEA; NEOPLASMS; OXYCODONE; PAIN; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SLEEP STAGES; TREATMENT OUTCOME; VOMITING;

EID: 42549113996     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn010     Document Type: Article

References (35)

1. World Health Qrganization. Cancer Pain Relief. 2nd edn. Geneva, Switzerkand: World Heath Organization 1996, 1-69.
2. American Pain Society. Principles of Analgesic use in the Treatment of Acute Pain and Cancer Pain. 5th edn. Glenview, IL: American Pain Society 2003; 16.
3. Reder RF. Opioid formulations: Tailoring to the needs in chronic pain. Eur J Pain 2001;5:109-11.
4. Kalso E. Oxyiodone. J Pain Symptom Manage 2005;29:S47-56.
5. Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer 2005; 13:145-52.
6. Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of world health organization guidelines for cancer pain relief: A 10-year prospective study. Pain 1995;63:65-76.
7. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology, Pain 200 1;93:247-57.
8. Kalso E, Allan L, Dellernijn PLI, Faura C, Ilias WK, Jensen TS, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-6.
9. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-40.
10. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H et al. Strategies no manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 2001;19:2542-54.
11. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20:348-52.
12. Mercadante S,Portenoy RK. Opioid poorly-responsive cancer pain. part 1: clinical considerations. J Pain Symptom Manage 2001;21:144-50.
13. Mercadante S, Portenoy RK. Opioid poorly responsive cancer pain. part 3: clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001;21:338-54.
14. Expert Working Group of the European Association for Palliative Care. Fortnightly review:MMorphine in cancer pain: modes of administration. Br Med J 1996;312:823-6.
15. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
16. Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999;86:1856-66.
17. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability the applicatiom of alternate opioid therapy. Pain 1993;53:353-5.
18. Doyle D, Hanks G, Cherny N, et al. Oxford Textbook of Palliative Medicine. 3rd edn. Oxford, UK: Oxford University Press 2005;333-3a4.
19. Morita T, Takigawa C, Onish Hi, Tajima T, Tani K, Matsubara T, et al. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage 2005;30:96-103.
20. Wirz S, Wartenberg HC, Eisen C, Wirrmann M, Diederichs M, Nadstawek J. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: A prospective clinical trial. Clin J. Pain 2006;22:770-5.
21. Moryl N, Kogan M, Comfort C, Obbens E. Methadone in the treatment of pain and terminal delirium in advanced cancer patients. Palliat Support Care 2005;3:311-7.
22. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patient. Support Care Cancer 2006;14:56-64.
23. Lugo RA,Kern SE. Clinical pharmacokinetics of morphine. J Pain 2002;16:5-18.
24. Kaiko RF, Benziger DP, Fitzmartin RD Burke BE, Reder RF, Goldenheirm PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodonv. Clin Pharmacol Ther 1996;59:52-61.
25. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharnig6okinetics. and metabolism of oxytodone after intramuscular and oral administration to healthy subjects. Br J clin Pharmacol 1992;33.611-21.
26. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: A comparison of six methods. Pain 198;27:477-26.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 1631-4 1.
28. Bruera V, Relzile M, Pitutskin,E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized: Double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controfled-release morphine in patients with caffcer pain. J Clin Ocol 1998;16:3222-9.
29. Shimizu T, Saijo N! Common Toxicity Criteria: Version 2.0, an important, reference for grading-the adverse ceaction of cancer treatment Nippon Rinsho 2003;61:937-942 (in Japanese).
30. Barnett M. Alterilative opioids to morphine in palliative care: A review of current practice and evidence. Postgrad Med J 200 1;77:371-8.
31. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, et al. Controlledwrelease oxycodone compared with controlled-Release morphine in the -treatmentof cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239-49.
32. Kaiko R,'Benziger D,-Cheng C, HouA1, Grandy R. Clinical pharmacokinctics of conirolled-release oxycodone in renal impairment. Clin Pharmarol Ther 1996;59:130.
33. Pauli-Magnus t, Hofmann U, Mikus G, Kuhlmann Mettang T. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peitoneal dialysis. Nephrol Dial Transplant 1999;14:903-9.
34. Reder RF, Oshlack B, Miotto JB, Benziger DO, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther 1996; 18:95-105.
35. Grandy RP, Benziger DP, Tan CC, Kaiko RF., Pharmacokinetics of conventional and controlled-release oxyeodone formulations. IASP. 8th World Congress on Pain 1996:228.